Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

3.2K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of endocannabinoid catabolizing enzymes MAGL and FAAH reduces the activity of CaV3 channels in nociceptors and pain hypersensitivity in a rat model of spinal cord injury.

The journal of pain·2026
Same author

SBFI Inhibitors Reprogram Transcriptomic Landscape of Prostate Cancer Cells Leading to Cell Death.

Cancers·2025
Same author

The emerging role of fatty acid-binding protein 3 (FABP3) in cancer.

Drug discovery today·2025
Same author

Variability in Self-Reported Preoperative Pain Between Clinic Visits and Day of Surgery.

Cureus·2025
Same author

Acute Pain After Total Knee Arthroplasty: 2-Arachidonoylglycerol Tone and Endocannabinoid/Eicosanoid Crosstalk.

Anesthesia and analgesia·2025
Same author

Cyan Thermal Proteins Derived From Thermal Green Protein.

Proteins·2025

Related Experiment Video

Updated: Apr 16, 2026

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

10.1K

Evaluating FABP5 as a Therapeutic Target for Pain Management.

William Warren1, Myles Osborn1, Martin Kaczocha2

  • 1Artelo Biosciences Ltd, Alderley Park, Alderley Edge, Cheshire, UK.

European Journal of Pain (London, England)
|April 15, 2026
PubMed
Summary

Fatty acid-binding protein 5 (FABP5) inhibition shows promise as a novel analgesic strategy. Targeting FABP5 may offer a safe, non-opioid, and non-steroidal approach for managing complex pain conditions.

More Related Videos

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

13.4K
Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

6.0K

Related Experiment Videos

Last Updated: Apr 16, 2026

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

10.1K
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

13.4K
Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

6.0K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Pain Research

Background:

  • Fatty acid-binding proteins (FABPs) are intracellular lipid transporters.
  • FABP5 inhibition demonstrates analgesic effects in preclinical pain models.
  • Genetic manipulation of FABP5 also induces analgesia in certain pain conditions.

Purpose of the Study:

  • To review the evidence supporting FABP5 modulation as an analgesic strategy.
  • To explore the mechanisms underlying FABP5's role in pain.
  • To assess the potential of FABP5 inhibitors for pain management.

Main Methods:

  • Literature search of PubMed (January-August 2025).
  • Inclusion of studies on FABP5 inhibition, genetic ablation, analgesia, pain behaviors, and signaling pathways.
  • Analysis of preclinical data on FABP5 modulation in pain.

Main Results:

  • FABP5 inhibition mediates analgesia via lipid-signaling receptors (CB1, PPARα, TRPV1).
  • FABP5 inhibitors modulate inflammatory pathways, suppressing cytokines like TNF and interleukins.
  • A specific FABP5 inhibitor, ART26.12, exhibited a favorable safety profile in preclinical studies.

Conclusions:

  • Preclinical data support FABP5 inhibitors as novel analgesics.
  • Further research is needed on sex differences and chronic dosing.
  • FABP5 inhibition presents a promising non-opioid and non-steroidal pain management strategy.